SEC Form 4 · accession 0001415889-19-000250
CELGENE CORP /DE/ · CELG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alise Reicin
Officer — PRES., GLOBAL CLINICAL DEV.
Period of report
Mar 1, 2019
Accepted (ET)
Mar 5, 2019 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816284
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF3,F1,F2 | — | Mar 1, 2019 | A | 37,660 | A | — | — | Common Stock | 37,660 | 37,660 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
- F2The restricted stock units will vest in three equal annual installments, beginning on March 1, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date.
- F3The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan.
Remarks
President, Inflammation and Immunology